Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

Novartis day

Novartis plans major expansion of French antibody facility

Project aims to boost capacity by 70% and create new jobs

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

- PMLiVE

Rare blood cancer therapy Oncaspar gets NICE green light

Baxalta’s acute lymphoblastic leukaemia treatment recommended for NHS use

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links